Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 880

1.

Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin.

Krikken JA, Waanders F, Dallinga-Thie GM, Dikkeschei LD, Vogt L, Navis GJ, Dullaart RP.

Expert Opin Ther Targets. 2009 May;13(5):497-504. doi: 10.1517/14728220902905865 .

PMID:
19397474
3.

Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.

Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Olijhoek JK, Visseren FL.

Clin Endocrinol (Oxf). 2008 Dec;69(6):870-7. doi: 10.1111/j.1365-2265.2008.03250.x. Epub 2008 Apr 3.

PMID:
18394022
4.

Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome.

de Zeeuw D, Gansevoort RT, Dullaart RP, de Jong PE.

J Hypertens Suppl. 1995 Jul;13(1):S53-8.

PMID:
18800457
5.

Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment.

Vogt L, Laverman GD, van Tol A, Groen AK, Navis G, Dullaart RP.

Nephrol Dial Transplant. 2006 Jan;21(1):101-6. Epub 2005 Sep 2.

PMID:
16141462
6.

Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.

Kappelle PJ, Zwang L, Huisman MV, Banga JD, Sluiter WJ, Dallinga-Thie GM, Dullaart RP.

Expert Opin Ther Targets. 2009 Jul;13(7):743-51. doi: 10.1517/14728220903023866.

PMID:
19505224
7.

Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.

Seiler S, Schlitt A, Jiang XC, Ulrich C, Blankenberg S, Lackner KJ, Girndt M, Werdan K, Buerke M, Fliser D, Heine GH.

Nephrol Dial Transplant. 2008 Nov;23(11):3599-604. doi: 10.1093/ndt/gfn296. Epub 2008 May 25.

PMID:
18503096
8.

Cholesteryl ester transfer protein in metabolic syndrome.

Sandhofer A, Kaser S, Ritsch A, Laimer M, Engl J, Paulweber B, Patsch JR, Ebenbichler CF.

Obesity (Silver Spring). 2006 May;14(5):812-8.

9.
10.
11.

Decreased plasma cholesterol esterification and cholesteryl ester transfer in hypopituitary patients on glucocorticoid replacement therapy.

Beentjes JA, van Tol A, Sluiter WJ, Dullaart RP.

Scand J Clin Lab Invest. 2000 May;60(3):189-98.

PMID:
10885490
15.

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ.

N Engl J Med. 2004 Apr 8;350(15):1505-15.

16.

Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies.

Ruggenenti P, Mise N, Pisoni R, Arnoldi F, Pezzotta A, Perna A, Cattaneo D, Remuzzi G.

Circulation. 2003 Feb 4;107(4):586-92.

17.

Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia.

Napoli C, Leccese M, Palumbo G, de Nigris F, Chiariello P, Zuliani P, Somma P, Di Loreto M, De Matteis C, Cacciatore F, Abete P, Liguori A, Chiariello M, D'Armiento FP.

Coron Artery Dis. 1998;9(5):257-64.

PMID:
9710685
19.

Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes.

van Hoek M, van Tol A, van Vark-van der Zee LC, Jansen H, Kastelein JJ, Sijbrands EJ, Dallinga-Thie GM.

Curr Med Res Opin. 2009 Jan;25(1):93-101. doi: 10.1185/03007990802596813 .

PMID:
19210142
20.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Heart. 2008 Jun;94(6):706-14. doi: 10.1136/hrt.2007.125401. Review.

PMID:
18480348

Supplemental Content

Support Center